Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has high recurrence and lethality rates.
• Many patients cannot complete adjuvant systemic therapy after surgery.
• Current guidelines recommend neoadjuvant therapy mainly for borderline-resectable and locally advanced disease.

Purpose of the Study:

• To review current prospective data on neoadjuvant systemic therapy for resectable PDAC.
• To highlight the evolving treatment paradigm for resectable PDAC.
• To discuss the role of neoadjuvant chemotherapy in resectable PDAC.

Main Methods:

• Review of recent prospective clinical trials and multi-institutional data.
• Analysis of systemic chemotherapy regimens in the neoadjuvant setting for PDAC.
• Evaluation of data relevant to resectable PDAC treatment.

Main Results:

• Emerging data supports the use of neoadjuvant systemic chemotherapy in resectable PDAC.
• Multi-institutional trials provide new insights into neoadjuvant treatment efficacy.
• A shift in treatment strategies towards neoadjuvant therapy is observed globally.

Conclusions:

• Neoadjuvant systemic therapy is becoming a key component in the management of resectable PDAC.
• Prospective data is crucial for refining treatment guidelines for resectable PDAC.
• The paradigm for treating resectable PDAC is shifting towards neoadjuvant approaches.